ScholarIQanswers from OpenAlex & ORCID
Robert E. Gerszten
ResearcherPublications, citations & collaboration network
Robert E. Gerszten is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Robert E. Gerszten have?
ScholarIQindexed works
Robert E. Gerszten has 583 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Robert E. Gerszten have?
ScholarIQcitation count
Robert E. Gerszten has 48,505 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Robert E. Gerszten?
ScholarIQh-index
Robert E. Gerszten has an h-index of 107 in OpenAlex.
What is the i10-index of Robert E. Gerszten?
ScholarIQi10-index
Robert E. Gerszten has an i10-index of 287 in OpenAlex.
What is the ORCID of Robert E. Gerszten?
ScholarIQorcid
The ORCID for Robert E. Gerszten is on the source record.
What is the OpenAlex record for Robert E. Gerszten?
ScholarIQopenalex
The OpenAlex for Robert E. Gerszten is on the source record.
What are the most-cited papers on Robert E. Gerszten?
ScholarIQmost cited works
Assessment of Echocardiography and Biomarkers for the Extended Prediction of Cardiotoxicity in Patients Treated With Anthracyclines, Taxanes, and Trastuzumab
Heloisa Sawaya, Igal A. Sebag, Juan Carlos Plana, James L. Januzzi, Bonnie Ky, Timothy C. Tan, Victor Cohen, José Banchs, Joseph R. Carver, Susan E. Wiegers, Randolph P. Martin, Michael H. Picard, Robert E. Gerszten, Elkan F. Halpern, Jonathan Passeri, Irene Kuter, Marielle Scherrer‐Crosbie
Early Detection and Prediction of Cardiotoxicity in Chemotherapy-Treated Patients
Heloisa Sawaya, Igal A. Sebag, Juan Carlos Plana, James L. Januzzi, Bonnie Ky, Victor Cohen, Sucheta Gosavi, Joseph R. Carver, Susan E. Wiegers, Randolph P. Martin, Michael H. Picard, Robert E. Gerszten, Elkan F. Halpern, Jonathan Passeri, Irene Kuter, Marielle Scherrer‐Crosbie
Early Increases in Multiple Biomarkers Predict Subsequent Cardiotoxicity in Patients With Breast Cancer Treated With Doxorubicin, Taxanes, and Trastuzumab
Bonnie Ky, Mary Putt, Heloisa Sawaya, Benjamin French, James L. Januzzi, Igal A. Sebag, Juan Carlos Plana, Victor Cohen, José Banchs, Joseph R. Carver, Susan E. Wiegers, Randolph P. Martin, Michael H. Picard, Robert E. Gerszten, Elkan F. Halpern, Jonathan Passeri, Irene Kuter, Marielle Scherrer‐Crosbie
Understanding the Cellular and Molecular Mechanisms of Physical Activity-Induced Health Benefits
P. Darrell Neufer, Marcas M. Bamman, Deborah M. Muoio, Claude Bouchard, Dan M. Cooper, Bret H. Goodpaster, Frank W. Booth, Wendy M. Kohrt, Robert E. Gerszten, Mark P. Mattson, Russell T. Hepple, William E. Kraus, Michael B. Reid, Sue C. Bodine, John M. Jakicic, Jerome L. Fleg, John P. Williams, Lyndon Joseph, Mary E. Evans, Padma Maruvada, Mary M. Rodgers, Mary Roary, Amanda Boyce, Jonelle K. Drugan, James I. Koenig, Richard H. Ingraham, Danuta Krotoski, Mary L. Garcı́a-Cazarı́n, Joan McGowan, Maren R. Laughlin
Longitudinal proteomic analysis of severe COVID-19 reveals survival-associated signatures, tissue-specific cell death, and cell-cell interactions
Michael R. Filbin, Arnav Mehta, Alexis M. Schneider, Kyle R. Kays, Jamey Guess, Matteo Gentili, Bánk G. Fenyves, Nicole C. Charland, Anna Gonye, Irena Gushterova, Hargun K. Khanna, Thomas J. LaSalle, Kendall M. Lavin-Parsons, Brendan M. Lilley, Carl L. Lodenstein, Kasidet Manakongtreecheep, Justin Margolin, Brenna McKaig, Maricarmen Rojas-López, Brian C. Russo, Nihaarika Sharma, Jessica Tantivit, Molly Thomas, Robert E. Gerszten, Graham Heimberg, Paul Hoover, David Lieb, Brian Lin, Debby Ngo, Karin Pelka, Miguel Reyes, Christopher S. Smillie, Avinash Waghray, Thomas E. Wood, Amanda S. Zajac, Lori L. Jennings, Ida Grundberg, Roby P. Bhattacharyya, Blair A. Parry, Alexandra–Chloé Villani, Moshe Sade-Feldman, Nir Hacohen, Marcia B. Goldberg